Literature DB >> 14992973

Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.

Delbert G Robinson1, Margaret G Woerner, Marjorie McMeniman, Alan Mendelowitz, Robert M Bilder.   

Abstract

OBJECTIVE: Follow-up studies have found that a substantial number of patients with schizophrenia achieve full recovery (i.e., sustained improvement in both symptoms and social/vocational functioning) when examined decades after an index admission. This study addressed recovery during the crucial early course of the illness.
METHOD: Subjects in their first episode of schizophrenia or schizoaffective disorder (N=118) were assessed at baseline and then treated according to a medication algorithm. Full recovery required concurrent remission of positive and negative symptoms and adequate social/vocational functioning (fulfillment of age-appropriate role expectations, performance of daily living tasks without supervision, and engagement in social interactions).
RESULTS: After 5 years, 47.2% (95% CI=36.0%-58.4%) of the subjects achieved symptom remission, and 25.5% (95% CI=16.1%-34.7%) had adequate social functioning for 2 years or more. Only 13.7% (95% CI=6.4%-20.9%) of subjects met full recovery criteria for 2 years or longer. Better cognitive functioning at stabilization was associated with full recovery, adequate social/vocational functioning, and symptom remission. Shorter duration of psychosis before study entry predicted both full recovery and symptom remission. More cerebral asymmetry was associated with full recovery and adequate social/vocational functioning; a schizoaffective diagnosis predicted symptom remission.
CONCLUSIONS: Although some patients with first-episode schizophrenia can achieve sustained symptomatic and functional recovery, the overall rate of recovery during the early years of the illness is low.

Entities:  

Mesh:

Year:  2004        PMID: 14992973     DOI: 10.1176/appi.ajp.161.3.473

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  143 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

3.  Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.

Authors:  Philip R Szeszko; Katherine L Narr; Owen R Phillips; Joanne McCormack; Serge Sevy; Handan Gunduz-Bruce; John M Kane; Robert M Bilder; Delbert G Robinson
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

Review 4.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

Review 5.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 6.  Psychosocial treatments to promote functional recovery in schizophrenia.

Authors:  Robert S Kern; Shirley M Glynn; William P Horan; Stephen R Marder
Journal:  Schizophr Bull       Date:  2009-01-27       Impact factor: 9.306

7.  Schizophrenia research in 2013: are we making progress?

Authors:  Takeshi Sakurai; Leslie A Shinobu; Akira Sawa
Journal:  Neurobiol Dis       Date:  2013-02-01       Impact factor: 5.996

8.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

9.  Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches.

Authors:  Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell
Journal:  Am J Psychiatr Rehabil       Date:  2014-07

10.  Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome.

Authors:  Christoph U Correll; Julie B Penzner; Anne M Frederickson; Jessica J Richter; Andrea M Auther; Christopher W Smith; John M Kane; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2007-05-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.